---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027262"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T03:41:55.794633+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics reports 2023 annual meeting voting results

## Summary
- Elected Class I directors Epstein, Mendlein, Jooss with >65.8M 'for' votes each; 10.2M broker non-votes.
- Ratified Ernst & Young as auditor for FY2023: 85.5M for, 0.2M against, 1.2M abstentions.
- Approved non-binding advisory vote on executive compensation: 73.7M for, 3.0M against, 0.1M abstentions.
- Total shares present at meeting: 86.9M of 98.2M outstanding.

## SEC filing metadata
- accession: 0000950170-23-027262
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/0000950170-23-027262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/fate-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027262
- JSON: https://secwatch.observer/filing/0000950170-23-027262.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027262.txt

## Key facts
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Non-binding Advisory Vote on Compensation of Named Executive Officers. For Against Abstain Broker Non-Votes 73,720,442 2,955,503 61,938 10,211,752
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/0000950170-23-027262-index.htm
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 85,534,350 197,464 1,217,821 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/0000950170-23-027262-index.htm
- Shareholder Votes
  FATE THERAPEUTICS INC shareholders approved Election of three Class I Directors at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 74,088,457 2,649,426 10,211,752 John D. Mendlein, Ph.D., J.D. 65,801,671 10,936,212 10,211,752 Karin Jooss, Ph.D. 74,481,093 2,256,790 10,211,752
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027262/0000950170-23-027262-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.